Eric McIntyre
Investor Relations Contact at SPYRE THERAPEUTICS, INC.
Network origin in Eric McIntyre first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 19 | |
| Public Company | Pharmaceuticals: Major | 14 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Eric McIntyre via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Administrative Officer General Counsel Comptroller/Controller/Auditor Corporate Officer/Principal Corporate Officer/Principal | |
| ARENA PHARMACEUTICALS | Pharmaceuticals: Major | Director of Finance/CFO | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO Compliance Officer | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| KYTHERA BIOPHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Investor Relations Contact Founder Director of Finance/CFO General Counsel | |
| SHIRE | Pharmaceuticals: Major | Director of Finance/CFO | |
PellePharm, Inc.
 PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Biotechnology | Founder | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree | |
| Stanford University | College/University | Doctorate Degree | |
| University of Pennsylvania | College/University | Doctorate Degree | |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor | |
| ALNYLAM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| MIRATI THERAPEUTICS | Biotechnology | Director of Finance/CFO | |
| University of California, Los Angeles | College/University | Undergraduate Degree Undergraduate Degree Masters Business Admin | |
| Arizona State University | College/University | Undergraduate Degree Undergraduate Degree | |
| University of California San Diego | College/University | Undergraduate Degree Undergraduate Degree | |
| The University of Queensland | College/University | Doctorate Degree | |
| Embry-Riddle Aeronautical University | College/University | Masters Business Admin | |
Dompe Biotec SpA
 Dompe Biotec SpA Pharmaceuticals: MajorHealth Technology Dompe Biotec SpA (Dompé Biotec SpA) provides biotechnological drugs. Its products are used for the treatment of haematology, infectious diseases, nephrology, oncology, transfusion units and neuro-oncology. The company was founded in 1988 and is headquartered in Milan, Italy | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Amgen Europe BV
 Amgen Europe BV Medical DistributorsDistribution Services Part of Amgen, Inc., Amgen Europe BV wholesales pharmaceutical products. The company is based in Breda, Netherlands. | Medical Distributors | Corporate Officer/Principal Director of Finance/CFO | |
Foodshare, Inc.
 Foodshare, Inc. Services to the Health IndustryHealth Services Foodshare, Inc. operates as a regional food bank serving Connecticut’s Hartford and Tolland counties. It provides food to local partner agencies such as community kitchens, food pantries, emergency shelters, senior food programs, child day care centers, and halfway houses. The company was founded in 1982 and is headquartered in Bloomfield, CT. | Services to the Health Industry | Director/Board Member | |
| Harvard Medical School | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
Therasis, Inc.
 Therasis, Inc. Pharmaceuticals: MajorHealth Technology Therasis, Inc. develops oncology drugs. It offers oncology therapeutics for use as single agents or in combination therapy. The firm's proprietary technology, the Therasis Filter, represents a paradigm shift in the ability to discover therapeutic targets, their chemical inhibitors, and associated biomarkers and this platform integrates world-class expertise in high throughput screening, systems biology, cancer genetics and clinical research. The company was founded by Owen A. O'Connor and Riccardo Dalla-Favera in 2007 and is headquartered in New York, NY. | Pharmaceuticals: Major | Director/Board Member | |
| KITE PHARMA INC | Biotechnology | Director of Finance/CFO Sales & Marketing | |
| THERAVANCE BIOPHARMA, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AXCA HEALPAR | Biotechnology | Corporate Officer/Principal General Counsel General Counsel | |
| UCLA Anderson School of Management | College/University | Masters Business Admin | |
| Harvard College | College/University | Undergraduate Degree | |
| PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
| SURFACE ONCOLOGY, INC. | Biotechnology | Director/Board Member | |
| UNITY BIOTECHNOLOGY, INC. | Biotechnology | Chairman Director of Finance/CFO General Counsel | |
| SIENNA BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chairman Director of Finance/CFO | |
Shire, Inc.
 Shire, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire, Inc. develops and markets medicines for patients with rare diseases. The company is based in Lexington, KY. | Pharmaceuticals: Major | Public Communications Contact | |
| VIRIDIAN THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| PROMETHEUS BIOSCIENCES, INC. | Biotechnology | Chief Executive Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Pharmaceuticals: Major | Chief Executive Officer | |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Pharmaceuticals: Major | Chief Executive Officer | |
| APOGEE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member Chief Executive Officer Chairman | |
Viridian LLC
 Viridian LLC BiotechnologyHealth Technology Viridian LLC operates as a biopharmaceutical incubator. It focuses in the discovery and development of new molecular entities. The company was founded by Peter Harwin and Tomas Kiselak in 2016 and is headquartered in Philadelphia, PA. | Biotechnology | Founder Founder | |
| DIANTHUS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
| BRIDGEBIO PHARMA, INC. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| LONGBOARD PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
| VENTYX BIOSCIENCES, INC. | Biotechnology | Corporate Officer/Principal | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Director of Finance/CFO |
Statistics
International
| United States | 46 |
| Ireland | 2 |
| Australia | 2 |
| Italy | 2 |
| Netherlands | 2 |
Sectoral
| Health Technology | 34 |
| Consumer Services | 12 |
| Commercial Services | 3 |
| Finance | 2 |
| Distribution Services | 2 |
Operational
| Director/Board Member | 109 |
| Corporate Officer/Principal | 85 |
| Independent Dir/Board Member | 55 |
| Undergraduate Degree | 28 |
| Director of Finance/CFO | 20 |
Most connected contacts
| Insiders | |
|---|---|
| Alison Lawton | 25 |
| Joseph Turner | 22 |
| John Smither | 20 |
| Keith Leonard | 20 |
| Ivana Magovcevic-Liebisch | 18 |
| Jeffrey Albers | 14 |
| Michael Henderson | 14 |
| Russell Cox | 13 |
| Laurie Stelzer | 13 |
| Mark Mckenna | 12 |
| Paul Fehlner | 11 |
| Peter Harwin | 11 |
| Rowe Heather Armstrong | 11 |
| Cameron Turtle | 11 |
| Tomas Kiselak | 10 |
- Stock Market
- Insiders
- Eric McIntyre
- Company connections
